Kenneth Rucker, MD
Internal Medicine · Durand, WINPI 1326088642
Payments from drug & device makers
Across 209 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$929
- Boehringer Ingelheim$662
- Amgen$285
- Pfizer$204
- Novartis$185
- Novo Nordisk$172
- plus $692 from 15 others
What the payments were for
- Food & beverage$3,118100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $929 |
| Boehringer Ingelheim | 43 | $662 |
| Amgen | 19 | $285 |
| Pfizer | 19 | $204 |
| Novartis | 12 | $185 |
| Novo Nordisk | 10 | $172 |
| Johnson & Johnson | 10 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $126 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Lilly USA, LLC | 5 | $65 |
| AstraZeneca | 3 | $43 |
| Exact Sciences | 2 | $32 |
| Medtronic | 2 | $28 |
| Bristol Myers Squibb | 2 | $25 |
| Grifols USA, LLC | 2 | $24 |
| GSK | 2 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Circassia Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$3,129 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $157,060 |
| TrulicityDulaglutide | 62 | $61,439 |
| JardianceEmpagliflozin | 70 | $41,151 |
| XareltoRivaroxaban | 62 | $32,235 |
| OzempicSemaglutide | 24 | $22,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,724 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $13,943 |
| MyrbetriqMirabegron | 25 | $12,025 |
| MounjaroTirzepatide | 11 | $11,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,399 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $7,886 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 26 | $7,779 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,472 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $6,417 |
| Levemir FlexpenInsulin Detemir | 29 | $4,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $157,060232 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $65 | $73,03373 claims |
| Boehringer IngelheimJardiance | $662 | $41,15170 claims |
| GSKIncruse Ellipta, Trelegy Ellipta, Arexvy, Breo Ellipta | $23 | $36,59393 claims |
| Johnson & JohnsonXarelto | $145 | $32,23562 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $43 | $23,61059 claims |
| Novo NordiskOzempic | $172 | $22,95824 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $12,02525 claims |
| AbbVieLumigan, Combigan | $929 | $5,48222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Durand
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.